ST3 beta-galactoside alpha-2,3-sialyltransferase 4 (ST3GAL4)

ST3 beta-galactoside alpha-2,3-sialyltransferase 4 (ST3GAL4) is an enzyme responsible for catalyzing the transfer of sialic acid from CMP-Neu5Ac onto galactose-terminated glycoconjugates, specifically the Galβ1,3-GalNAc and Galβ1,4-GlcNAc motifs on glycoproteins and glycolipids[3]. It is the primary human sialyltransferase controlling the biosynthesis of selectin ligands and the Sialyl Lewis X (sLeX) epitope on leukocyte N- and O-glycans, which are required for leukocyte adhesion and rolling during immune surveillance and vascular inflammation[1]. In acute myeloid leukemia (AML), ST3GAL4 synthesizes ligands for the inhibitory immune receptor Siglec-9, driving immune evasion by cancer cells[2]. Knockdown or inhibition of ST3GAL4 disrupts selectin ligand and Siglec-9 ligand expression and sensitizes cells to immune attack. The enzyme is considered a promising therapeutic target in cancer, with ongoing investigation of selectin and Siglec-9 targeting therapies[1][2][3].

Other names

CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4CGS23NANTA3SIAT4CSTZAlpha 2,3-ST 4Beta-galactoside alpha-2,3-sialyltransferase 4ST3GalIVSIAT4-CSAT3FLJ11867Alpha 2,3-sialyltransferase IVGal-NAc6SGal-beta-1,3-GalNAc-alpha-2,3-sialyltransferaseGal-beta-1,4-GlcNAc-alpha-2,3-sialyltransferaseN-acetyllactosaminide alpha-2,3-sialyltransferaseSAT-3ST-4ST3Gal IVST3GalA.2Sialyltransferase 4Cgal-NAc6Salpha 2,3-sialyltransferase IValpha-3-N-acetylneuraminyltransferasegal-beta-1,3-GalNAc-alpha-2,3-sialyltransferasegal-beta-1,4-GalNAc-alpha-2,3-sialyltransferasegal-beta-1,4-GlcNAc-alpha-2,3-sialyltransferasesialyltransferase 4C (beta-galactosidase alpha-2,3-sialytransferase)

Inhibition of ST3GAL4 reduces synthesis of Sialyl Lewis X and Siglec-9 ligands, attenuating immune evasion and leukocyte adhesion. Blocking ST3GAL4 can sensitize AML cells to macrophage phagocytosis